Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE BULLETIN
March 4, 2002
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 4, 2002
-
ARCHIVE Spin-off of Manufacturing Plants to Increase: PAL Revision
March 4, 2002
-
ARCHIVE 12,558 Drugstores Operated by 590 Companies: JACDS Survey
March 4, 2002
-
ARCHIVE Study Group Proposes Proper Drug Distribution System
March 4, 2002
-
ARCHIVE Taisho Appeals against Daikoku
March 4, 2002
-
ARCHIVE Manufacturers' FTC Issues Guide Regarding Entertainment
March 4, 2002
-
ARCHIVE Additional Premiums to Be Introduced in Medical Material Pricing System
March 4, 2002
-
ARCHIVE Kyowa Hakko to Transfer Its Liquor Business to Asahi Breweries
March 4, 2002
-
ARCHIVE Medical Devices to Be Re-priced to Reduce Domestic, Foreign Price Gaps
March 4, 2002
-
ARCHIVE Eisai's French Subsidiary Acquires All Shares of Biodim
March 4, 2002
-
ARCHIVE Fresenius-Kawasumi Completes 2nd Phase Construction on Inukai Plant
March 4, 2002
-
ARCHIVE Tsumura to Gear Up Kampo Business in China
March 4, 2002
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
March 4, 2002
-
ARCHIVE GE Information Supply Fee to Be Introduced: Revision -1-
March 4, 2002
-
ARCHIVE BUSINESS NEWS IN BRIEF
March 4, 2002
-
ARCHIVE WORLD NEWS IN BRIEF
March 4, 2002
-
ARCHIVE NEW PRODUCTS
March 4, 2002
-
ARCHIVE CORPORATE ROUNDUP NEWS IN BRIEF
March 4, 2002
-
ARCHIVE China Attracts Growing Number of Companies
March 4, 2002
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…